Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | GSR | P00390 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.47 |
| ▸ | GRM8 | O00222 | 2/20 | 0.47 |
| ▸ | GRM6 | O15303 | 2/20 | 0.47 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5187828 | 0.89 | ALOX15 (0.39) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL16054489 | 0.89 | ALOX15 (0.43) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL21753579 | 0.88 | SLC1A1 (0.53) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL2443865 | 0.88 | KMT2A (0.68) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL1410127 | 0.88 | SLC1A1 (0.48) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL7717181 | 0.85 | SLC1A1 (0.54) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL3430330 | 0.85 | SLC1A1 (0.54) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL6267781 | 0.85 | SLC1A1 (0.54) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL3918242 | 0.85 | SLC1A1 (0.54) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL931954 | 0.85 | SLC1A1 (0.54) | KMT2AALOX15BLMPMP22SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-02-11 | — | — | US | disclosed |
| EP-3737420-A2 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| WO-2019136487-A2 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20180291077-A1 | METHOD OF INSULIN PRODUCTION | HANMI PHARM. CO., LTD (KR) | 2018-10-11 | — | — | US | disclosed |
| EP-3341405-A1 | METHOD OF INSULIN PRODUCTION | Hanmi Pharm. Co., Ltd. (KR) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017052305-A1 | METHOD OF INSULIN PRODUCTION | HANMI PHARM. CO., LTD. (KR) | 2017-03-30 | — | — | WO | disclosed |
| US-20020151482-A1 | Plasminogen-related gene B Polypeptides | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2002-10-17 | — | — | US | disclosed |
| WO-1999058640-A2 | MCT-1, A HUMAN ONCOGENE | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
| EP-0391629-B1 | Inhibition of mineral deposition by phosphorylated and related polyanionic peptides | UNIV SOUTH ALABAMA (US) | 1997-05-21 | — | — | EP | disclosed |
| US-5051401-A | A phospho aminoacid polymer as an antideposit agent | UNIVERSITY OF SOUTH ALABAMA (US) | 1991-09-24 | — | — | US | disclosed |
| EP-0391629-A1 | Inhibition of mineral deposition by phosphorylated and related polyanionic peptides | UNIVERSITY OF SOUTH ALABAMA (US) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040144-A1 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | KMT2A 4548/4885ALOX15 2615/4885BLM 3502/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | KMT2A 4548/4885ALOX15 2615/4885BLM 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.